In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens.
We studied the in-vitro activity of HMR 3004 (RU 64004), a new ketolide, against 161 clinical isolates of Corynebacterium spp. including isolates resistant to erythromycin A, josamycin and lincomycin. HMR 3004 was active against all erythromycin A-sensitive isolates as well as against 75.8% and 45.4% of erythromycin A-intermediate and -resistant isolates, respectively. In contrast, HMR 3004 was active against 40 (46.5%) of 86 isolates resistant to erythromycin A, josamycin and lincomycin as well as against two isolates that were resistant to erythromycin A and lincomycin but not resistant (i.e. susceptible or intermediate) to josamycin.
Soriano
F
F
Department of Medical Microbiology, Fundación Jiménez Díaz, Madrid, Spain. fsoriano@microb.net
Fernández-Roblas
R
R
Calvo
R
R
García-Calvo
G
G
Pardeiro
M
M
Bryskier
A
A
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003352:Corynebacterium / Q000187:drug effects*; D003354:Corynebacterium Infections / Q000382:microbiology; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000494:pharmacology*; D006801:Humans; D015570:Josamycin / Q000494:pharmacology; D048628:Ketolides; D008034:Lincomycin / Q000494:pharmacology; D018942:Macrolides; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C105420:RU 64004; D004917:Erythromycin; D008034:Lincomycin; D015570:Josamycin